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1. Introduction 
Angiotensin-converting enzyme (EC 3.4.15.1) is a 
mammalian COOH-terminal dipeptidyl peptidase which 
catalyzes the release of His-Leu from angiotensin I 
to yield angiotensin II [ 11, the vasoactive agent of the 
renin-angiotensin system [2]. The same enzyme 
inactivates bradykinin, a vasodepressor nonapeptide, 
by cleavage of the COOH-terminal and adjacent 
dipeptides [3,4]. We have recently shown, using 
specific fluorescein-labeled antibody, that converting 
enzyme is present in the luminal cells of the vascula- 
ture of every organ examined, including lung, liver, 
kidney, pancreas, adrenal and spleen [5]. While extra- 
pulmonary conversion [6-91 and converting activity 
[lO,l l] are well documented, the lung is thought to 
play an important role in both conversion of angio- 
tensin I to II [ 12,131 and the degradation of brady- 
kinin [ 141 in the circulation. This is because the lung 
is perfused by the entire circulating blood volume and 
has a very large capillary surface area. Further, 
enzymatically generated angiotensin II is not taken up 
by the lung [ 13,151 but delivered to the systemic 
circulation where it exerts its pressor effect. Recent 
immunohistochemical evidence has indicated that 
pulmonary converting enzyme may be localized on the 
luminal surface of the endothelial cells [ 161. The 
possibility that converting enzyme is accessible to 
circulating antibodies prompted us to examine the 
effects in vivo of antibody with anticatalytic activity. 
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We found that goat antibodies specific for rabbit 
pulmonary converting enzyme produce a lethal reac- 
tion when administered intravenously in the rabbit. At 
lower dosage permitting limited survival, there is 
inhibition of the vasopressor esponse to angiotensin 
I and potentiation of the vasodepressor effect of 
bradykinin. 
2. Materials and methods 
Hippurylhistidylleucine (Hip-His-Leu) was from 
Research Plus and (l-Asp, 5-Ile) angiotensins I and II 
were from Schwarz/Mann. Bradykinin triacetate was 
a Sigma product. Pure solubilized rabbit lung con- 
verting enzyme was obtained as described [ 171. 
Antibody was raised and maintained in goats by 
monthly intradermal injections of 150 pg of enzyme 
in 1 ml of 0.15 M NaCl emulsified with an equal 
volume of complete Freund’s adjuvant. Anticatalytic 
activity was determined by preincubating antibody 
for 30 min at 37°C with pure enzyme in 10 mM Tris- 
HCl, pH 7.5, containing 0.15 M NaCl and assaying 
residual enzyme activity with Hip-His-Leu as sub- 
strate [ 181. Sera were heated at 56°C for 30 min and 
centrifuged for 60 min at 105 000 g. Globulins were 
obtained by addition of solid (NH4)#.04 to 50% 
saturation. The precipitate was dissolved and dialyzed 
extensively against Tris-NaCl buffer. Protein concen- 
trations in serum and globulin fractions were estimated 
using A&g values of 9.0 and 14.1, respectively. 
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liminary operation by insertion of indwelling Long- responses prior to antibody infusion. Typical results 
dwell 20 gauge 8 inch catheters (Becton Dickinson) are shown in figs.1 and 2. Further, the pressor response 
into the right atrium for intravenous administration to angiotensin II was not immediately altered. The 
and aortic arch for blood pressure determinations. 
Catheters were exteriorized for later use in the awake, 
unanaesthetized animal and were occluded with a 
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Teflon monofilament obturator. Prior to administra- 
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vasoactive agent. 
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3. Results 
Fig.1. Effect of antibody on vasopressor response to angio- 
tensin I. Dose responses were determined before and 30 min 
after infusion of 0.5 ml of immune globulin. The administered 
Immune sera and globulin fractions showed a 
ammonium sulfate fraction contained 24 mg of protein and 
sufficient anticatalytic activity to inhibit the action of 1.4 mg 
single precipitin band after immunodiffusion against of pure enzyme by 50% in vitro. 
the pure enzyme and exhibited anticatalytic activity 
in vitro. Initially a dose of antibody was employed B 
which contained approx. twice the anticatalytic d I 
activity required to inhibit the total lung content 
(1.5 mg) of pure enzyme by 50% in vitro. Recipient 
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rabbits given this dose invariably died of acute pul- 
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monary edema, accompanied by hypotension, within 
30 min after receiving antibody. Equivalent amounts 
of protein from preimmune sera, which exhibited no 
anticatalytic activity in vitro, were well tolerated and 
did not produce any change in the dose response of 
angiotensin I. To determine whether immune fractions 
demonstrated anticatalytic effects in vivo it was 
necessary to use the maximum amount of antibody 
which did not cause immediate death. The recipient z I 
rabbits given this lesser dose all died within 3-6 days 
and there was a progressive fall in their mean arterial 
pressure of about 15 mm Hg during this period. 
BRADYKININ (pg) 
Autopsy in these animals revealed pulmonary con- Fig.2. Effect of antibody on the vasodepressor response to 
gestion and hemorrhage. Within 30 minutes after 
bradykinin. The experiment was carried out as described for 
administration of antibody the pressor effect of angio- 
fig. 1, except that the infused immune globulin solution con- 
tensin I was decreased and the depressor action of 
tained 28 mg of protein and anticatalytic activity sufficient 
to inhibit 0.4 mg of pure enzyme by 50% in vitro. 
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decreased pressor response to angiotensin I persisted 
for as long as four days in some animals, although 
by this time the vasopressor effect of angiotensin II 
was also diminished to a lesser extent, perhaps because 
of the debilitated state of these animals. 
4. Discussion 
Angiotensin-converting enzyme is a surface glyco- 
protein which is thought to be directly accessible to 
the circulating blood and which can be solubihzed and 
isolated as a pure, highly antigenic molecule. These 
characteristics render it unique as a model for studying 
specific surface immunologic phenomena in vivo and 
for exploring the possibility that enzyme activity can 
be regulated by exogenous antibody. The most striking 
result which we have observed is the immediate 
immune-specific lethality of antibody directed against 
the enzyme. The pulmonary injury is almost certainly 
not due to anticatalytic activity per se, since venom 
peptide inhibitors of the enzyme are remarkably non- 
toxic [ 19,201. The injury may be the result of an 
immune reaction on the capillary endothelial cell 
surface, perhaps associated with the release of ana- 
phylactic mediators. The predominance of lung 
pathology could be explained by the fact that the 
capillary bed of this organ is the first exposed to 
antibody after intravenous administration. 
Those animals which temporarily survived the lower 
dose of antibody showed a diminished vasopressor 
response to angiotensin as compared with angiotensin 
II, whereas the vasodepressor response to bradykinin 
was potentiated. These results suggest hat inhibition 
of enzyme activity by specific antibody may have 
occurred in vivo. The duration of antibody effect 
was considerably longer than that reported for peptide 
inhibitors which have been shown to prevent initiation 
of experimental, renin-dependent hypertension [19,20] 
Clearly, however, dissociation of the lethal and anti- 
catalytic actions of the antibody preparations will be 
required for the development of a useful regulatory 
immunologic reagent. 
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